Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine Inhalation Solution for BOS-free survival after lung transplant (CYCLIST)
NCT00755781Phase 3Completed
- Sponsor
- APT Pharmaceuticals
- Start
- Sep 2008
- Primary completion
- Sep 2011
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Cyclosporine Inhalation Solution in Bronchiolitis Obliterans Syndrome (BOS) (2 arms), sponsored by APT Pharmaceuticals. Primary endpoint: Bronchiolitis Obliterans Syndrome-Free Survival at 3 years. Started Sep 2008; status: completed.
02
Drugs
Cyclosporine Inhalation Solution
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT00755781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00755781.